Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Sci Rep ; 10(1): 6301, 2020 04 14.
Artigo em Inglês | MEDLINE | ID: mdl-32286449

RESUMO

Gadolinium-based contrast agents (GBCAs) are frequently used in patients undergoing magnetic resonance imaging. In GBCAs gadolinium (Gd) is present in a bound chelated form. Gadolinium is a rare-earth element, which is normally not present in human body. Though the blood elimination half-life of contrast agents is about 90 minutes, recent studies demonstrated that some tissues retain gadolinium, which might further pose a health threat due to toxic effects of free gadolinium. It is known that the bone tissue can serve as a gadolinium depot, but so far only bulk measurements were performed. Here we present a summary of experiments in which for the first time we mapped gadolinium in bone biopsy from a male patient with idiopathic osteoporosis (without indication of renal impairment), who received MRI 8 months prior to biopsy. In our studies performed by means of synchrotron radiation induced micro- and submicro-X-ray fluorescence spectroscopy (SR-XRF), gadolinium was detected in human cortical bone tissue. The distribution of gadolinium displays a specific accumulation pattern. Correlation of elemental maps obtained at ANKA synchrotron with qBEI images (quantitative backscattered electron imaging) allowed assignment of Gd structures to the histological bone structures. Follow-up beamtimes at ESRF and Diamond Light Source using submicro-SR-XRF allowed resolving thin Gd structures in cortical bone, as well as correlating them with calcium and zinc.


Assuntos
Meios de Contraste/análise , Osso Cortical/diagnóstico por imagem , Gadolínio/análise , Biópsia , Meios de Contraste/administração & dosagem , Meios de Contraste/farmacocinética , Osso Cortical/química , Osso Cortical/patologia , Osso Cortical/ultraestrutura , Gadolínio/administração & dosagem , Gadolínio/isolamento & purificação , Gadolínio/farmacocinética , Meia-Vida , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Osteoporose/diagnóstico por imagem , Espectrometria por Raios X/instrumentação , Síncrotrons , Fatores de Tempo , Distribuição Tecidual
2.
Appl Radiat Isot ; 130: 131-139, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28963960

RESUMO

The goal of this study was to investigate the production, purification and immobilization techniques for a 153Gd brachytherapy source. We have investigated the maximum attainable specific activity of 153Gd through the irradiation of Gd2O3 enriched to 30.6% 152Gd at McMaster Nuclear Reactor. The advantage of producing 153Gd through this production pathway is the possibility to irradiate pre-sealed pellets of 152Gd enriched Gd2O3, thereby removing the need to perform chemical separation with large quantities of radio-impurities. However, small amounts of long-lived impurities are produced from the irradiation of enriched 152Gd targets due to traces of Eu in the sample. If the amount of impurities produced is deemed unacceptable, 153Gd can be isolated as an aqueous solution, chemically separated from impurities and loaded onto a sorbent with a high affinity for Gd before encapsulation.


Assuntos
Braquiterapia/métodos , Gadolínio/uso terapêutico , Terapia por Captura de Nêutron/métodos , Radioisótopos/uso terapêutico , Gadolínio/isolamento & purificação , Humanos , Reatores Nucleares , Radioisótopos/isolamento & purificação , Dosagem Radioterapêutica
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA